Why Lilly Paid $6.3 Billion for Sleep Science

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with an additional $1.5 billion in potential milestone payments tied to regulatory approvals.1 The deal gives Lilly full ownership of Centessa's pipeline of orexin receptor 2 agonists, a class of compounds designed to directly modulate the neurobiological system governing the sleep-wake cycle.

The acquisition signals meaningful commercial and scientific momentum behind orexin receptor biology, a target area that has attracted growing attention following the clinical success of orexin antagonists in insomnia.1 Where that earlier wave focused on blocking the pathway to promote sleep, Centessa's compounds take the opposite approach, activating the receptor to restore wakefulness in patients whose orexin signaling is impaired or absent.

Centessa's lead compound, cleminorexton, has completed Phase IIa studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.1 The pipeline also includes additional clinical and preclinical-stage assets with potential utility in neurodegenerative and neuropsychiatric conditions.

"Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle. Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications," said Carole Ho, executive vice president and president of Neuroscience, Lilly, stated in a press release.1 "Joining forces with Centessa colleagues means we can now pursue that potential at the speed and scale it deserves."

What Does This Mean for Drug Development Timelines and Regulatory Strategy?

Lilly is paying $38.00 per share in cash at closing, plus a non-transferable contingent value right worth up to $9.00 per share, for a total potential per-share consideration of $47.00.1 The contingent payments are tied to three specific milestones: $2.00 upon FDA approval of cleminorexton or ORX142 for narcolepsy type 2 before the fifth anniversary of closing; $5.00 upon FDA approval of either compound for idiopathic hypersomnia within the same window; and $2.00 upon the first FDA approval of either compound for any indication before January 1, 2030. The upfront cash represents a roughly 40.5% premium to Centessa's 30-day volume-weighted average trading price as of March 30, 2026.

The milestone structure reflects the regulatory complexity still ahead.1 Idiopathic hypersomnia in particular remains an area with limited approved treatments and evolving diagnostic criteria, factors that development and regulatory affairs teams will be tracking closely as Lilly advances these programs. The January 2030 hard deadline on one of the contingent payments adds a concrete timeline pressure that will shape how Lilly prioritizes its clinical execution post-close.

Mario Alberto Accardi, chief executive officer, Centessa and founder of the orexin program, stated in the press release.1 "By combining Centessa's team and capabilities with Lilly's global complementary research, clinical, regulatory and commercial capabilities, we will seek to accelerate the advancement of our orexin portfolio across a broad range of neuroscience indications for the benefit of patients in need."

How Will the Transaction Be Structured?

The acquisition will be carried out through a scheme of arrangement under the laws of England and Wales.1 It requires approval from Centessa's shareholders and sanction from the High Court of Justice of England and Wales, in addition to standard regulatory clearances. Shareholders representing approximately 24.1% of Centessa's outstanding ordinary shares have already signed voting and support agreements committing to approve the transaction.

The post-close integration will be a key area to watch.1 Centessa's pipeline is still largely in clinical stages, meaning chemistry, manufacturing, and controls strategies, supply chain buildout, and process development work for commercial-scale manufacturing remain ahead. How Lilly integrates Centessa's scientific team and institutional knowledge of the orexin program will determine how quickly these compounds can move through the pipeline and ultimately reach patients.

Accardi stated, in the press release,1 "Driven by a bold vision, our team has advanced an innovative portfolio with the speed, rigor and conviction needed to lead a new era of orexin-based therapeutics. This milestone reflects not only the strength of our science, but also the transformative potential of our orexin portfolio for patients who urgently need new solutions."

Is Lilly Building a Broader Neuroscience and Immunology Platform?

The Centessa acquisition is not an isolated move.2 Just days earlier, Lilly presented Phase IIIb data showing that combining its biologic Taltz with its obesity medication Zepbound delivered statistically superior outcomes in adults managing both psoriatic arthritis and obesity, a population representing roughly 65% of patients with psoriatic arthritis in the United States. The trial met its primary and all key secondary endpoints at 36 weeks, with improvements spanning disease activity, fatigue, physical function, and cardiometabolic markers. Together, these developments suggest Lilly is deliberately expanding into complex, comorbidity-driven patient populations where single-mechanism therapies have historically fallen short.

References

1. Eli Lilly and Company and Centessa Pharmaceuticals plc. Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders. Indianapolis (IN) and Boston (MA) and London (UK): Eli Lilly and Company and Centessa Pharmaceuticals plc; 2026 Mar 31. Available from: https://investors.centessa.com/news-releases/news-release-details/lilly-acquire-centessa-pharmaceuticals-advance-treatments-sleep
2. Eli Lilly and Company. Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity. Indianapolis (IN): Eli Lilly and Company; 2026 Mar 28. Available from: https://investor.lilly.com/news-releases/news-release-details/phase-3b-data-presented-aad-annual-meeting-show-lillys-taltz